Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
1.02T
Market cap1.02T
Price-Earnings ratio
53.24
Price-Earnings ratio53.24
Dividend yield
0.56%
Dividend yield0.56%
Average volume
3.80M
Average volume3.80M
High today
$1,083.48
High today$1,083.48
Low today
$1,057.25
Low today$1,057.25
Open price
$1,076.72
Open price$1,076.72
Volume
2.63M
Volume2.63M
52 Week high
$1,111.99
52 Week high$1,111.99
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $1,064.37, with a market capitalization of 1.02T. The stock trades at a price-to-earnings (P/E) ratio of 53.24 and offers a dividend yield of 55.7%.

As of 2025-12-23, Eli Lilly(LLY) stock has fluctuated between $1,057.25 and $1,083.48. The current price stands at $1,064.37, placing the stock +0.7% above today's low and -1.8% off the high.

Eli Lilly(LLY) shares are trading with a volume of 2.63M, against a daily average of 3.8M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.

LLY News

MarketWatch 1h
Novo Nordisk first out of the gate with oral weight-loss drug and its stock jumps

Before, they had to be injected, but now Novo Norkish has secured FDA approval for the oral version of its Wegovy weight-loss drug - beating its rival Eli Lilly...

Novo Nordisk first out of the gate with oral weight-loss drug and its stock jumps
TipRanks 4h
Novo Nordisk Stock Pops as FDA Approves Wegovy Weight Loss Pill

Novo Nordisk (NVO) stock surged 9.5% in Monday’s extended trading session as the Danish drugmaker scored the U.S. Food and Drug Administration’s (FDA) approval...

Nasdaq 11h
Why Abivax Stock Was on Fire Today

Key Points New speculation arose about a potential buyout from a very deep-pocketed strategic investor. These first started to swirl in mid-December. 10 stoc...

Why Abivax Stock Was on Fire Today

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
19.4%
Sell
3.2%

More LLY News

Investor's Business Daily 12h
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug

Technology Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug Licensing The Food and Drug Administration approved a pill form o...

Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug
TipRanks 1d
Why Is Abivax Stock Rallying Today? Big Pharma Takeover Buzz Builds

Abivax Société Anonyme (ABVX) shares jumped about 10% today after fresh media reports revived takeover speculation around the French biotech. French publication...

The Motley Fool 1d
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader. Shares of Novo Nordisk (NVO +1.0...

Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
Simply Wall St 3d
Has Lilly’s Obesity Drug Breakthrough Left Enough Upside After a 577% Five Year Surge?

If you are wondering whether Eli Lilly is still worth buying after its massive run up, or if the market has already priced in all the good news, you are not alo...

Has Lilly’s Obesity Drug Breakthrough Left Enough Upside After a 577% Five Year Surge?
Cheddar 4d
Eli Lilly’s New Pill Keeps the Weight Off

Eli Lilly’s New Pill Keeps the Weight Off Eli Lilly said its experimental daily obesity pill helped patients maintain most of their weight loss after switching...

Eli Lilly’s New Pill Keeps the Weight Off
Nasdaq 4d
Validea Detailed Fundamental Analysis - LLY

Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our Twin Momentum Investor m...

Validea Detailed Fundamental Analysis - LLY
TipRanks 4d
Eli Lilly: Reinforcing Obesity Market Leadership With Orforglipron and a Diversified Growth Pipeline

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Eli Lilly & Co, retaining the price target of $1,268.00. Claim 50% Off TipRanks...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.